GRIA3

Across TCGA pan-cancer cohorts, GRIA3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GRIA3 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GRIA3 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated GRIA3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

UCEC, KIRC, and BRCA are the cancer types where GRIA3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.955	0.310	.001	34	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
BRCA	OS	Median	III,IV	0.101	0.544	.042	6	view →
LUSC	DFS	Median	All	0.191	0.513	.025	2	view →
SCLC	OS	Median	II,III,IV	1.000	0.591	.046	1	view →
SKCM	DFS	Median	All	0.162	0.215	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GRIA3–UCEC (OS)

Open the UCEC breakdown →